Skip to main content
. Author manuscript; available in PMC: 2015 Mar 15.
Published in final edited form as: J Immunol. 2014 Feb 10;192(6):2576–2584. doi: 10.4049/jimmunol.1301857

Figure 4. DC-HIL−/− mice developed hyperacute EAE after immunization with MOG peptide.

Figure 4

WT (A) or DC-HIL KO (B) mice (n=11) were immunized similarly with MOG peptide and complete Freund's adjuvant, and EAE development monitored by scoring clinical symptoms. (C) Each clinical score on early- (day 10), mid- (day 20) or late-phases (day 30) was plotted in a scatter chart (median) with statistical significance of scores (*p<0.01) between WT and KO mice. Similarly, spinal cords of mice were examined histologically (D), and IFN-γ- or IL-17-producing cells from spleen of WT and KO mice counted and calculated (E). *p<0.0001 between WT and KO mice. Data are representative of 3 independent experiments.